LakeShore Biopharma Co (LakeShore Biopharma Co) Gross-Profit-to-Asset % : 25.74% (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. LakeShore Biopharma Co's annualized Gross Profit for the quarter that ended in Sep. 2023 was $60.54 Mil. LakeShore Biopharma Co's average Total Assets over the quarter that ended in Sep. 2023 was $235.18 Mil. Therefore, LakeShore Biopharma Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 25.74%.

LakeShore Biopharma Co Gross-Profit-to-Asset % Historical Data

The historical data trend for LakeShore Biopharma Co's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Gross-Profit-to-Asset % Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Gross-Profit-to-Asset %

16.91

29.92

32.50

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			35.57	24.98	38.92	28.15	25.74

Competitive Comparison of LakeShore Biopharma Co's Gross-Profit-to-Asset %

For the Biotechnology subindustry, LakeShore Biopharma Co's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Gross-Profit-to-Asset % falls into.

LakeShore Biopharma Co Gross-Profit-to-Asset % Calculation

LakeShore Biopharma Co's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Mar. 2023 )	/	( (Total Assets (A: Mar. 2022 )	+	Total Assets (A: Mar. 2023 ))	/ count )
	=	77.47	/	( (227.241	+	249.569)	/ 2 )
	=	77.47	/	238.405
	=	32.50 %

LakeShore Biopharma Co's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	60.54	/	( (249.569	+	220.787)	/ 2 )
	=	60.54	/	235.178
	=	25.74 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

LakeShore Biopharma Co Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.